These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 16005711)
41. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689 [TBL] [Abstract][Full Text] [Related]
42. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Bertheau P; Steinberg SM; Merino MJ Hum Pathol; 1998 Apr; 29(4):323-9. PubMed ID: 9563780 [TBL] [Abstract][Full Text] [Related]
43. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762 [TBL] [Abstract][Full Text] [Related]
44. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Ouatas T; Halverson D; Steeg PS Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3763-72. PubMed ID: 14506169 [TBL] [Abstract][Full Text] [Related]
45. The p53 and nm23-H1 genes are not deleted in oral benign epithelial lesions. Pavelic J; Gall-Troselj K; Mravak-Stipetic M; Pavelic K Anticancer Res; 1998; 18(5A):3527-31. PubMed ID: 9858935 [TBL] [Abstract][Full Text] [Related]
46. P53 expression in patients with malignant and benign breast diseases. Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110 [TBL] [Abstract][Full Text] [Related]
47. [Significance of p53, c-myc and nm23 protein expression in recurrent laryngeal carcinoma]. Guo R; Huang D; Yang W; Han D Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Mar; 17(3):161-3. PubMed ID: 12815897 [TBL] [Abstract][Full Text] [Related]
48. [Expression of nm23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases]. Delektorskaia VV; Perevoshchikov AG; Kushlinskiĭ NE Arkh Patol; 2003; 65(5):11-5. PubMed ID: 14664140 [TBL] [Abstract][Full Text] [Related]
49. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358 [TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Krause FS; Feil G; Bichler KH Anticancer Res; 2000; 20(6D):5023-8. PubMed ID: 11326661 [TBL] [Abstract][Full Text] [Related]
51. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356 [TBL] [Abstract][Full Text] [Related]
52. Nm23-H1 expression does not predict clinical survival in colorectal cancer patients. Dusonchet L; Corsale S; Migliavacca M; Calò V; Bazan V; Amato A; Cammareri P; Totaro MS; Agnese V; Cascio S; La Rocca G; Sisto PS; Dardanoni G; Valerio MR; Grassi N; Latteri S; Cajozzo M; Buscemi M; Castorina S; Morello V; Tomasino RM; Gebbia N; Russo A Oncol Rep; 2003; 10(5):1257-63. PubMed ID: 12883690 [TBL] [Abstract][Full Text] [Related]
53. Lack of prognostic significance of nm23 expression in human primary breast cancer. Göhring UJ; Eustermann I; Becker M; Neuhaus W; Rein DT; Schöndorf T Oncol Rep; 2002; 9(6):1205-8. PubMed ID: 12375020 [TBL] [Abstract][Full Text] [Related]
54. Micrometastasis and expression of nm23 messenger RNA of lymph nodes from lung cancer and the postoperative clinical outcome. Ayabe T; Tomita M; Matsuzaki Y; Ninomiya H; Hara M; Shimizu T; Edagawa M; Onitsuka T; Hamada M Ann Thorac Cardiovasc Surg; 2004 Jun; 10(3):152-9. PubMed ID: 15312010 [TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Visscher DW; Sarkar F; Tabaczka P; Crissman J Mod Pathol; 1996 Jun; 9(6):642-6. PubMed ID: 8782201 [TBL] [Abstract][Full Text] [Related]
56. Immunohistologic detection of nm23-H1 protein in squamous cell carcinoma of the vulva. Hantschmann P; Beysiegel S; Assemi C; Kurzl R J Reprod Med; 2004 Oct; 49(10):787-95. PubMed ID: 15568401 [TBL] [Abstract][Full Text] [Related]
57. [Relevant factors of nm23 protein expression and dangerous factors of bone metastasis in breast cancer]. Xiong LJ; Liang CH; Deng HY Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Feb; 29(1):75-8. PubMed ID: 16137012 [TBL] [Abstract][Full Text] [Related]
58. p53 expression in cytologic specimens from benign and malignant breast lesions. Koutselini H; Malliri A; Field JK; Spandidos DA Anticancer Res; 1991; 11(4):1415-9. PubMed ID: 1746898 [TBL] [Abstract][Full Text] [Related]
59. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230 [TBL] [Abstract][Full Text] [Related]
60. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]